A Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 (STING agonist) in combination with intravenous ezabenlimab for treatment of advanced solid tumors (NCT05471856)

Zoom

DLT, dose-limiting toxicity; ECOG PS, Eastern Cooperative Oncology Group performance status; MTD, maximum tolerated dose; OR, objective response; STING, stimulator of interferon genes.